MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcin.2012.04.008

Медицинская библиотека · JACC. Cardiovascular interventions · 2012

3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents.

Maeng Michael, Tilsted Hans-Henrik, Jensen Lisette Okkels, Kaltoft Anne, Kelbæk Henning, Abildgaard Ulrik, Villadsen Anton B, Krusell Lars Romer, Ravkilde Jan, Hansen Knud Nørregaard, Christiansen Evald Høj, Aarøe Jens, Jensen Jan Skov, Kristensen Steen Dalby, Bøtker Hans Erik, Madsen Morten, Thayssen Per, Sørensen Henrik Toft, Thuesen Leif, Lassen Jens Flensted

Сравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVES

This study sought to examine the 3-year clinical outcomes in patients treated with the Endeavor (Medtronic, Santa Rosa, California) zotarolimus-eluting stent (ZES) or the Cypher (Cordis, Johnson & Johnson, Warren, New Jersey) sirolimus-eluting stent (SES) in routine clinical practice.

BACKGROUND

The long-term clinical outcome in patients treated with ZES in comparison with SES is unclear.

METHODS

The authors randomized 2,332 patients to ZES (n = 1,162) or SES (n = 1,170) implantation. Endpoints included major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction, or target vessel revascularization; the individual endpoints of MACE; and definite stent thrombosis.

RESULTS

At 3-year follow-up, the MACE rate was higher in patients treated with ZES than in patients treated with SES (148 [12.9%] vs. 116 [10.1%]; hazard ratio [HR]: 1.33, 95% confidence interval [CI]: 1.04 to 1.69; p = 0.022). Target vessel revascularization was more frequent in the ZES group compared with the SES group (103 [9.1%] vs. 76 [6.7%]; HR: 1.40, 95% CI: 1.04 to 1.89; p = 0.025), whereas the occurrence of myocardial infarction (3.8% vs. 3.3%) and cardiac death (2.8% vs. 2.8%) did not differ significantly. Although the rate of definite stent thrombosis was similar at 3-year follow-up (1.1% vs. 1.4%), very late (12 to 36 months) definite stent thrombosis occurred in 0 (0%) patients in the ZES group versus 12 (1.1%) patients in the SES group (p = 0.0005).

CONCLUSIONS

Although the 3-year MACE rate is higher in patients treated with ZES versus SES, our data highlight a late safety problem concerning definite stent thrombosis with the use of SES. This finding underscores the importance of long-term follow-up in head-to-head comparisons of drug-eluting stents. (Randomized Clinical Comparison of the Endeavor and the Cypher Coronary Stents in Non-selected Angina Pectoris Patients [SORT OUT III]; NCT00660478).

Для цитирования: Maeng Michael, Tilsted Hans-Henrik, Jensen Lisette Okkels, Kaltoft Anne, Kelbæk Henning, Abildgaard Ulrik, Villadsen Anton B, Krusell Lars Romer, Ravkilde Jan, Hansen Knud Nørregaard, Christiansen Evald Høj, Aarøe Jens, Jensen Jan Skov, Kristensen Steen Dalby, Bøtker Hans Erik, Madsen Morten, Thayssen Per, Sørensen Henrik Toft, Thuesen Leif, Lassen Jens Flensted. 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents.. JACC. Cardiovascular interventions. 2012. DOI: 10.1016/j.jcin.2012.04.008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.